Glioblastoma is the most common primary malignant brain tumor in adults and is associated with poor survival. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a randomized, multi-institution clinical trial to evaluate immune responses and survival following neoadjuvant and/or adjuvant therapy with pembrolizumab in 35 patients with recurrent, surgically resectable glioblastoma. Patients who were randomized to receive neoadjuvant pembrolizumab, with continued adjuvant therapy following surgery, had significantly extended overall survival compared to patients that were randomized to receive adjuvant, post-surgical programmed cell death protein 1 (PD-1) 
G lioblastoma, with an incidence of 3.2 per 100,000 population, is the most common primary malignant central nervous system tumor and carries an abysmal 3-year survival rate of just 10.1% (ref. 1 ). The median progression-free survival in primary glioblastoma is 6.9 months, and median overall survival is 14.6 months with standard of care surgery, radiation therapy and temozolomide 2 . In recurrent glioblastoma, median overall survival is an estimated 24-44 weeks [3] [4] [5] . New therapies are needed for patients diagnosed with this type of cancer.
Among the array of cancer immunotherapeutics available, PD-1 monoclonal antibody blockade has yielded promising results in patients with metastatic cancer [6] [7] [8] [9] [10] [11] [12] . PD-1 inhibition is thought to disrupt the engagement of PD-1 with its inhibitory ligands, spurring cytotoxic T cell-mediated tumor elimination 10, 13 . Pembrolizumab, an anti-PD-1 monoclonal antibody, has demonstrated benefit as monotherapy in multiple cancer types 14, 15 , but primarily in the adjuvant setting 16 . However, a preclinical metastatic breast cancer study suggested that neoadjuvant immune checkpoint inhibition could generate enhanced and sustained antitumor immune responses, resulting in a survival benefit over adjuvant therapy alone 17 . Such concepts were recently validated by a small single-arm clinical study in resectable lung cancer 18 , a small randomized trial in melanoma 19 as well as a phase 2 trial in melanoma comparing neoadjuvant nivolumab to neoadjuvant nivolumab with ipilimumab 20 . All studies demonstrated enhanced T cell responses and a clinical benefit with neoadjuvant checkpoint inhibition.
To date, PD-1 blockade has demonstrated limited efficacy in patients with glioblastoma, except in isolated case reports associated Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma and 12 in the adjuvant-only arm. In the intention-to-treat analysis, patients in the neoadjuvant arm demonstrated a statistically significant increase in overall survival, with a hazard ratio of 0.39 compared to the adjuvant-only group (95% confidence interval 0.17-0.94; P = 0.04, log-rank test). Patients in the adjuvant-only group had a median overall survival of 228 d (7.5 months), whereas those in the neoadjuvant arm had a median overall survival of 417 d (13.7 months; Fig. 1a ). Median progression-free survival was 72.5 d (2.4 months) in the adjuvant-only group and 99.5 d (3.3 months) in the neoadjuvant group (hazard ratio 0.43; 95% confidence interval 0.20-0.90; P = 0.03, log-rank test; Fig. 1b and Extended Data Fig. 2 ). However, the establishment of progression-free survival may be complicated by pseudoprogression (Fig. 1c) , a finding previously observed in malignant glioma patients treated with immunotherapy [31] [32] [33] . In patients that received surgery and had histologic evidence of tumor (n = 15 patients per group), the median overall survival of the neoadjuvant treatment cohort was 400 d (13.2 months) from registration date, while that of the adjuvant treatment cohort was 192 d (6.3 months; hazard ratio 0.35, 95% confidence interval 0.14-0.88; P = 0.03, log-rank test).
Neoadjuvant PD-1 blockade induces distinct tumoral gene expression changes.
To evaluate whether neoadjuvant PD-1 blockade would alter the gene expression profile of recurrent glioblastoma, we first analyzed transcriptional changes within patient tumors utilizing direct multiplexed messenger RNA (mRNA) quantification. We analyzed the differential gene expression between treatment groups, which revealed several statistically significant differences in tumor samples (Supplementary Table 2 ). Kyoto Encyclopedia of Genes and Genomes gene set 
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NaTurE MEDICINE enrichment analysis identified gene products associated with cytokine-cytokine interaction, the chemokine signaling pathway and the Toll-like receptor signaling pathway. To quantify the T cell-inflamed microenvironment, we compared an immunerelated gene expression signature score ( Supplementary Table 3 ) 34 between treatment groups. There was a significant transcriptional increase in genes related to interferon-γ responsiveness (P = 0.03, U = 49; Mann-Whitney U-test; Fig. 2a and Extended Data Fig. 3 ).
We also sought to determine whether neoadjuvant PD-1 blockade would induce other transcriptional changes in these tumors. As such, we performed RNA sequencing on patient tumor samples and applied an unbiased screen for differentially expressed gene signatures with an interquartile range >1. Our data demonstrated interferon-and T cell-pathway induction in 9 of 14 tumors in the neoadjuvant group and 5 of 15 in the adjuvant-only group, corroborating our mRNA quantification data. In addition, 3 out of 14 tumors in the neoadjuvant group demonstrated positive enrichment of cell cycle/cancer proliferation signatures, whereas this occurred in 11 of 15 tumors in the adjuvant group ( Fig. 2b ; two-sided P = 0.01, Fisher exact test, 95% confidence interval 0.01-0.70). We found no statistically significant correlation between steroid dose at registration and signature scores for representative interferon, T cell and cell cycle gene expression. The proportion of cell cycle signatures in our study as a whole was similar to that of publicly available RNA sequencing datasets from patients with recurrent glioblastoma 35 
Fig. 1 | Neoadjuvant pembrolizumab confers significant improvement in overall and progression-free survival in patients with recurrent glioblastoma.
Patients in the neoadjuvant arm (red) received 200 mg pembrolizumab 14 ± 5 d before surgical resection; patients in the adjuvant-only arm (blue) did not; both groups received 200 mg adjuvant pembrolizumab every 3 weeks. a, Kaplan-Meier plot of overall survival. Median overall survival for patients receiving adjuvant treatment only was 228.5 d, whereas median survival in the neoadjuvant group was 417 d (hazard ratio 0.39 neoadjuvant/adjuvant; P = 0.04 by log-rank test, n = 35 patients). b, Swimmer plot of individual patients depicting start and stop times of dexamethasone or equivalent (as recorded at study magnetic resonance imaging (MRI) visit) and/or bevacizumab, if applicable, as well as time to progression, in days after enrollment. Bars represent overall survival in days. Rightward arrow indicates that the patient was still alive at the time of final data collection. c, Serial MRI scans of a representative patient from the neoadjuvant group. The patient, a 66-year-old female in first recurrence, is IDH negative and MGMT unmethylated. PD, progression of disease; pembro, pembrolizumab; Tx, treatment.
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Neoadjuvant PD-1 antibody blockade is associated with focal upregulation of PD-L1 and CD8 + T cell infiltrate in recurrent glioblastoma. To address whether neoadjuvant PD-1 blockade would increase the infiltration of T cells, we quantified the immune cell infiltrate in each patient's tumor tissue via multiplex immunofluorescence. The density of tumor-infiltrating CD8 + T cells was not different between groups but demonstrated significant variability in the neoadjuvant cohort. Because PD-L1 is known to be upregulated in response to interferon-γ produced by infiltrating T cells 34,37-39 , we evaluated whether PD-L1 would be increased with neoadjuvant PD-1 blockade. Samples were classified as having either a constitutive, focal or negative PD-L1 expression pattern with varying degrees of CD8 + T cell infiltration. Seven neoadjuvant patients and three adjuvant patients exhibited a focal phenotype with a high CD8 infiltrate ( Fig. 3 and Supplementary Table 4 ), suggesting that neoadjuvant treatment is associated with focal induction of PD-L1 expression. Qualitatively, the focal upregulation of PD-L1 in the adjuvant cases was not as striking, suggesting that the endogenous functional T cell response was not as dramatic. Articles | FOCUS that the clinical effectiveness of neoadjuvant PD-1 blockade might occur because this specific timing resulted in a detectable local and systemic T cell response. To test this, we performed αβ T cell receptor sequencing on all patients' peripheral blood mononuclear cells at baseline, at the time of surgery and at approximately 6 weeks after surgery, as well as on all evaluable tumor samples. We statistically identified T cell receptor rearrangements that were differentially abundant in each patient's peripheral blood mononuclear cells at on-treatment time points relative to baseline and quantified the number of clones that significantly increased in frequency ( Fig. 4a ) as well as the proportion of T cell receptors shared between tumor and blood (Fig. 4b ). There was a trend toward an increased number of expanded clones between baseline and surgery in the neoadjuvant compared with the adjuvant group (two-sided P = 0.07, unpaired t-test). We observed no significant differences in tumor-infiltrating lymphocyte content, T cell receptor diversity or proportion of T cell receptors shared between tumor and blood by treatment group or clinical time point. However, in neoadjuvant patients, we noted commensurate increases in the fraction of expanded T cell clones following the post-surgery PD-1 blockade cycle and T cell recep-tor overlap between tumor and blood across all three collected time points (r s = 0.86, 0.84, 0.89; P = 0.0002, 0.0003, 0.00004, respectively, asymptotic t approximation, n = 25 patients). Similarly, the amount of T cell receptor overlap at the time of surgery was also significantly associated with the tumor-infiltrating lymphocyte fraction, but only in the neoadjuvant treatment group (r s = 0.83; P = 0.0005, asymptotic t approximation, n = 25 patients; Fig. 4c ). These correlations were not found in the adjuvant-only group, suggesting that neoadjuvant PD-1 blockade uniquely initiated a coordinated local and systemic T cell response.
Neoadjuvant PD-1 blockade is associated with monocytic and T cell phenotypic changes.
To evaluate whether neoadjuvant PD-1 blockade would alter the phenotype of systemic immune cell populations, we performed time-of-flight mass cytometry on peripheral blood samples collected from study subjects at baseline, before surgery and after receiving at least one adjuvant treatment cycle, enabling use of the adjuvant group as a concurrent control. After staining and sample acquisition, we concatenated a total of 84 samples. We utilized unsupervised clustering to conduct cell Bottom, a sample from a patient in the adjuvant-only group demonstrates high CD8 infiltration with focal PD-L1 expression; however, the degree of PD-L1 expression is lower. The images at the far left are depicted at lower magnification to demonstrate the difference between focal and constitutive PD-L1 expression and are representative of the entire tumor section/ slide. Images second from left show staining for CD8; in the images second from the right, PD-1 stains are superimposed; and on the far right, the images depict co-staining for CD8, PD-1 and PD-L1. Multiplex staining was performed in one standardized run per patient. For each staining run, two sequential slides were used as duplicates for each patient. Computational analysis was performed two or more times per sample. Fig. 6 ) and evaluated the characteristics of the identified clusters. There was a statistically significant decrease in an intermediate monocyte population in the neoadjuvant group between baseline and after at least one cycle of adjuvant PD-1 blockade, which was not observed in the adjuvant-only group (baseline mean proportion 1.35 ± 0.31% versus on-treatment mean proportion 0.56 ± 0.12%; Benjamini-Hochberg-corrected, two-sided P = 0.007, general linear hypothesis test, n = 28; Fig. 4d ). We then compared the expression of functional markers within clustered cell populations and noted statistically significant decreases in PD-1 and increases in CTLA-4 (Benjamini-Hochberg-corrected, two-sided P = 0.025 and 0.0015, respectively, general linear hypothesis test, n = 28) on CD4 + T cell clusters ( Fig. 4e ) solely in the neoadjuvant group between baseline and post-surgery. After correcting for multiple comparisons, no significant changes were observed in peripheral blood mononuclear cell populations from the adjuvant-only treatment group.
Cell cycle gene signature, baseline T cell receptor clonality and tumor-infiltrating lymphocyte density may be associated with clinical response to neoadjuvant PD-1 blockade.
Finally, we sought to determine which clinical and laboratory factors were directly associated with survival, utilizing an elastic net-regularized Cox regression for variable selection. In the 30 patients with evaluable tumor, neoadjuvant PD-1 blockade therapy, IDH mutation status, lower baseline peripheral T cell receptor clonality and increased tumor-infiltrating lymphocyte density were associated with increased overall survival. We then fit these variables, combined with age and sex, into a Cox proportional hazards regression and confirmed that neoadjuvant treatment was associated with improved survival (hazard ratio 0.33, P = 0.045; Supplementary  Table 5 ). Standardized baseline peripheral T cell receptor clonality trended toward a survival association, with a hazard ratio of 1.48 for each standard deviation increase of 1 (P = 0.12). Given the significant treatment effect on the cell cycle signature in neoadjuvant patients, we sought to determine whether a representative gene set 40 could be utilized as a biomarker for overall survival, calculating the R 2 statistic to evaluate the potential predictive power 41 . We found that the cell-cycle-related gene set variation analysis enrichment score explained 57% of the variance in overall survival (R 2 = 0.57). When added to the previous Cox model, the R 2 value increased from 0.36 to 0.62, suggesting that the cell cycle gene set variation analysis enrichment score may be one of the most significant predictors of overall survival.
Discussion
In this study, PD-1 monoclonal antibody blockade was associated with statistically significant improvements in overall survival and progression-free survival when administered in the neoadjuvant setting to patients with recurrent glioblastoma. We leveraged T cell receptor sequencing, mRNA expression profiling, quantitative multiplex immunofluorescence and mass cytometry on patient blood and tumor samples to understand the distinct biological effects induced by this neoadjuvant timing. Our data suggest that neoadjuvant PD-1 monoclonal antibody blockade induces functional activation of tumor-infiltrating lymphocytes, producing an interferon response within the tumor microenvironment. Tumor infiltration with interferon-γ-producing, PD-1/PD-L1-suppressed T cells is probably essential for the systemic priming of tumorspecific T lymphocytes after neoadjuvant pembrolizumab. Indeed, tumor-infiltrating lymphocyte density was one of the variables selected in our elastic net regression as being possibly related to survival; conversely, presurgical tumor volume, postsurgical tumor volume, percentage resection, gross total resection (as a dichotomous variable) and dexamethasone dosage at time of registration were not. This suggests that the survival benefit derived from neoadjuvant PD-1 blockade is largely driven by the immune response. After neoadjuvant PD-1 blockade and resection, tumorspecific T cell clones maintained functionality with repeated anti-PD-1 monoclonal antibody administration in the adjuvant setting ( Fig. 5 ). We believe that the T cell-mediated interferon response induces downregulation of cell-cycle-related gene expression within tumor cells, enabling a therapeutic window and resulting in a survival benefit. It is already known that many interferon-regulated gene products block cell cycle activities and tumor cell proliferation [42] [43] [44] , suggesting that the transcriptional suppression of such cell-cycle-related genes is a key feature of the efficacy for PD-1 blockade. Of note, a single-arm phase 2 clinical trial by Melero and colleagues 45 in this same issue, utilizing neoadjuvant nivolumab in newly diagnosed or relapsed glioblastoma (NCT02550249), demonstrated intratumoral and systemic immune changes similar to those found by us.
In our gene expression analysis of tumor samples, we noted an upregulation of interferon-γ-related gene products in patients who received neoadjuvant PD-1 blockade, whereas patients without this upregulation demonstrated enrichment of cell cycle pathway gene sets. In fact, in a murine neoadjuvant immunotherapy model of breast cancer, the neutralization of interferon-γ nullified the efficacy of neoadjuvant anti-PD-1 plus anti-CD137 antibody therapy, indicating a vital role in promoting antitumor activity 17 . This, together with our data, strongly suggests that increased interferon-γ signaling is a consequence of anti-PD-1 therapy and mediator of the functional immunologic response. Our study indicates that, although increased interferon signaling occasionally occurs in the presence of recurrent glioblastoma (as demonstrated by patients in the adjuvant-only group with upregulated interferonγ-related gene expression), checkpoint release in the presence of tumor (i.e., in the neoadjuvant setting) may be a crucial component in the enhancement of tumor-specific T cell effector function, a finding consistent with that observed by Liu et al. 17 in a murine model. In addition, mice that received no treatment and no surgery demonstrated increased tumor-specific T cells, but poor effector function compared to groups that received neoadjuvant therapy and tumor resection, suggesting that both timing and surgery may play a role in tumor-specific T cell expansion. A similar mechanism may account for the failure of anti-PD-1 therapy in recurrent, unresected glioblastoma 24 .
Quantitative multiplex immunohistochemistry revealed an increased proportion of patients in the neoadjuvant group that exhibited focal upregulation of PD-L1. However, three patients in the adjuvant-only group also demonstrated this finding, albeit with qualitatively limited PD-L1 intensity. Two of these three patients also demonstrated upregulation of cell-cycle-related genes, suggesting that their endogenous T cell response was insufficient to disrupt tumor cell proliferation. The third patient, with focal PD-L1 upregulation on multiplex immunofluorescence, exhibited some CD8 + T cell infiltration but did not have an elevated cell cycle signature. The T cell-and interferon-related genes also were not increased, suggesting an aberrant mixture of low-level activity. The overall survival of these three patients was below the median for all patients.
After analyzing the T cell receptor data, we found that expansion of tumor-associated T cell receptor clones in the neoadjuvant group after treatment was correlated with high overlap between tumor and blood. While the overall number of expanded clones did increase after the initial pembrolizumab dose in the adjuvant-only group, these additional correlations were not seen. This suggests that PD-1 blockade can lead to increases in T cell clones regardless of timing; however, pre-surgical checkpoint inhibition enables a selective, primary tumor-specific T cell clonal modulation, driving systemic expansion of tumor-specific T lymphocytes.
Neoadjuvant pembrolizumab was not associated with a significant change in T cell receptor diversity, supporting previous findings that diversification of the T cell repertoire is not mediated via the PD-1 axis 46 . However, as our data indicate that increased baseline T cell receptor clonality may be associated with reduced survival, it appears that greater initial T cell diversity may portend improved responsiveness to PD-1 blockade. Our data suggest a role for combination immunotherapy with CTLA-4 blockade, which was shown to increase the number and complexity of T cell receptor variants in patients with melanoma 46 and has been demonstrated to be efficacious in other tumor types 12 . Although this combination was evaluated in a small cohort of recurrent glioblastoma patients lacking an obvious survival signal 47 , it has yet to be explored in a neoadjuvant investigation.
In our single-cell peripheral blood analysis, no specific cell population appeared to consistently predict survival, contrasting with previous studies in other cancer types [48] [49] [50] . In our evaluation of differentially expressed functional markers on various cell populations, CD4 + T cells demonstrated statistically significant increases in CD152 and CD127 and a decrease in PD-1, suggesting that the degree of phenotypic shift toward activation and memory may play a significant role in the post-surgical antitumor immune response.
Because of the established role of corticosteroid usage in the treatment of both central nervous system malignancies and immune-related adverse events, we evaluated the correlation between dexamethasone dosage at the time of registration as continuous and dichotomous variables and expression scores of interferon-, T cell-and cell-cycle-related gene sets, as well as overall survival. We found no statistically significant correlations, differing from published findings in patients with non-small-cell lung cancer that received PD-1/PD-L1 blockade on high-dose baseline corticosteroids 51 . This may be due to the fact that the protocol for this study excluded patients receiving high-dose dexamethasone at baseline >4 mg day -1 . Many patients continued to receive, or were started on, low doses of dexamethasone during their treatment course. Our analyses corroborate previous findings that systemic corticosteroids can be utilized as management for adverse events without affecting objective response rates in patients receiving nivolumab for advanced melanoma 52 .
Given the noted improvement in survival, we intend to expand the current study and pursue further clinical trials with neoadjuvant combination immunotherapeutics. Although this was a randomized clinical study, it was powered for tissue analyses. As such, interpretation of efficacy outcomes is limited by small sample size. Similarly, the observed immune effects may be influenced by an imbalance in the number of pembrolizumab doses received by patients in each group; the nature of this clinical trial design as a multicenter study also limited tissue availability for in-depth biologic analyses. We also did not find statistically significant correlations between patients that exhibited large numbers of expanded T cell clones, focal upregulation of PD-L1 expression and the above gene expression signature score. This may be due to the small sample size and/ or the heterogeneity in tumor sampling for quantitative multiplex immunofluorescence analysis. Notably, almost all patients in this study went on to receive bevacizumab. The precise role of bevacizumab is unclear, given the inter-patient heterogeneity in postprogression therapies and timing. Data suggest that bevacizumab in this setting is not associated with poorer survival outcomes 53 . Overall, the consistency of the data from this study indicates that there is an observable tissue-based and clinical treatment effect. 
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As such, the neoadjuvant approach to immunotherapy and brain cancer may provide a unique clinical development path while also providing a therapeutic window to study the immunobiology of malignant brain tumors.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/ s41591-018-0337-7.
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Methods Study design and patients. Patients were ≥18 years of age, had recurrent glioblastoma and were candidates for surgical debulking. Key eligibility criteria included Karnofsky performance status ≥70, previous first-line therapy with at least radiotherapy, first or second relapse with unequivocal evidence of tumor progression, adequate organ function, no high-dose systemic corticosteroids (defined as >4 mg day -1 of dexamethasone or bio-equivalent for at least three consecutive days within two weeks of registration) and absence of previous antiangiogenic or antivascular endothelial growth factor agents. All patients provided written informed consent; the study was approved by institutional review boards at all sites (Dana-Farber Cancer Institute; Huntsman Cancer Institute; MD Anderson Cancer Center; Massachusetts General Hospital; Memorial Sloan Kettering Cancer Center; University of California, Los Angeles; University of California, San Francisco) and was conducted according to the Declaration of Helsinki. After consent, patients randomized to the neoadjuvant group received pembrolizumab 200 mg by intravenous infusion 14 ± 5 d before scheduled surgical resection. Tumor resection was performed according to institutional standards. After recovery from surgery, patients received pembrolizumab 200 mg by intravenous infusion every 3 weeks until either tumor progression or an adverse event requiring study drug discontinuation. Blood samples were obtained every two cycles (6 weeks). Patients were followed for MRI changes, clinical exams and steroid doses until death or second progression. After second progression, patients were followed every 3 months for vital status until death.
RNA isolation and quantification. RNA was isolated from tumor sections stored in AllProtect tissue reagent (Qiagen) at the time of surgery; peripheral blood mononuclear cells were isolated at baseline, time of surgery and at cycle 2 of therapy and lysed to obtain RNA and protein. The nCounter GX analysis system (NanoString) was utilized to quantify RNA and protein expression according to the manufacturer's directions. The 770-gene nCounter PanCancer immune profiling panel was utilized (Nanostring; list of genes available from manufacturer).
RNA sequencing and gene set enrichment. Paired-end, 2 × 150 base pair (bp) transcriptome reads were mapped to the Genome Reference Consortium Human Build 38 (GRCh38) reference genome using HISAT2 (ref. 54 ). These raw sequencing files have been uploaded to the Gene Expression Omnibus (No. GSE121810). The gene level counts are generated by the HTSeq-count 55 program; we took log 2 counts per million (CPM) as normalized gene expression values. To calculate singlesample gene set enrichment, we used the Gene Set Variation Analysis (GSVA) package 56 to derive the absolute enrichment scores of the following perturbation gene sets from the Broad Institute's Molecular Signatures Database: 57 (1) c2.cgp.v6.0 (2) c6.all.v6.0 (3) c7.all.v6.0 (4) hallmark.v6.0 To ensure robustness, we chose only gene sets with at least 15 genes. We also included curated immune/stromal cell signatures from the CIBERSORT program 58 and from single-cell RNA sequencing studies on patient tumors 59 . To run GSVA, we first filtered out genes whose normalized expression's interquartile range is less than twofold (log 2 CPM interquartile range ≥ 1). The shortlisted genes' raw HTSeq-computed counts were then supplied to the GSVA program using the 'kcdf=Poisson' mode. Once the GSVA scores of all gene sets were computed, we selected those with GSVA score interquartile range ≥ 1 for further analysis.
Tumors with GSVA score ≥ 0.2 in both the 'T_generic' (reflecting general T cell activation markers) and ' Ayers_et_al_IFN_genes' (interferon activation signatures reported by Ayers et al. 34 ), and ≤0.2 in the 'FARMER_BREAST_CANCER_ CLUSTER_2' (reflecting cell-cycle-related genes), are defined as having high T cell infiltration and interferon pathway activation and decreased cell cycle. To evaluate for potential correlations between steroid administration and immune response, we calculated Spearman's rank correlation coefficient for steroid dose in milligrams at registration and the above representative gene sets for interferon-, T cell-and cell-cycle-related signature scores.
Finally, to compare the enrichments of the shortlisted gene sets within our datasets and that of other glioblastomas, we combined the log 2 CPM-normalized expression of The Cancer Genome Atlas (TCGA) glioblastomas (based on HTSeq-counts data downloaded from the Genomic Data Commons 60 ) and the pre-treatment RNA sequencing dataset GSE79671 (a study of patients with recurrent glioblastoma) with our own log 2 CPM and removed potential batch effects across the two datasets using the RemoveBatchEffect function in the limma R package. The combined CPM is input into the GSVA program using the default 'kcdf=Gaussian' option. We compared the statistical difference in the fraction of tumors with positive enrichment of each gene set, defined as having a GSVA score ≥0.2 for that gene set, in the neoadjuvant (n = 14), adjuvant (n = 15), GSE79671 (n = 20) and TCGA patient groups (n = 166) by one-sided Fisher exact test.
Immunosequencing of the T cell receptor β-chain. Genomic DNA was extracted from patient tumors and peripheral blood mononuclear cells (collected at baseline, before surgery, at the time of the first postsurgical pembrolizumab dose, every 6 weeks thereafter or at the end of treatment). Genomic DNA was extracted using the Qiagen DNeasy blood extraction kit. Utilizing the immunoSEQ Assay (Adaptive Biotechnologies) for peripheral blood mononuclear cell (PBMC) samples and the immunoSEQ Assay for formalin-fixed, paraffin-embedded tumor samples, T cell receptor-β (TCRβ) complementarity-determining region 3 (CDR3) regions were amplified and sequenced from 2 µg of genomic DNA (or all available extracted DNA if <2 µg was available). Regions were amplified using a bias-controlled multiplexed polymerase chain reaction method, followed by high-throughput sequencing. Sequences were collapsed and filtered to identify and quantitate the absolute abundance of each unique TCRβ CDR3 for further analysis as previously described [61] [62] [63] .
To measure tumor-infiltrating lymphocyte density, the immunoSEQ Assay for formalin-fixed, paraffin-embedded tumor samples amplifies both the TCRβ CDR3 and selected reference genes, which quantitate the total number of T cells and nucleated cells, respectively. Tumor-infiltrating lymphocyte density is calculated by dividing the total number of T cells by the total number of nucleated cells.
We assessed T cell receptor overlap between tumor-infiltrating lymphocytes and PBMCs as previously described 64 . To summarize, T cell receptor overlap between tumor and PBMC samples from each patient was assessed by identifying the shared TCRβ CDR3 amino acid sequences found between two samples. The sum of shared sequences between two samples was then divided by the total number of unique TCRβ CDR3 sequences present across both samples. To evaluate T cell receptor diversity, we utilized the Daley-Smith Richness estimator, a Bayesian approach that enables characterization of the complexity of DNA sequencing data; this methodology provides an estimate of repertoire diversity that is robust to differences in input DNA between samples 65 .
No significant difference was observed in the number of expanded clones between treatment groups from baseline to surgery (two-sided P = 0.40, Wilcoxon rank sum test with continuity correction, W = 101, 95% confidence interval -7.0 to 44.0, n = 26 independent biological samples) or from surgery to the second adjuvant cycle (two-sided P = 0.89, Wilcoxon rank sum test with continuity correction, W = 101.5, 95% confidence interval -22.0 to 28.0, n = 28 independent biological samples). We also did not observe significant differences in tumorinfiltrating lymphocyte content (two-sided P = 0.41, Wilcoxon rank sum test, W = 133, 95% confidence interval -0.006 to 0.019, n = 30 independent biological samples), T cell receptor diversity in tumor (two-sided P = 1, Wilcoxon rank sum test, W = 113, 95% confidence interval -0.05 to 0.06, n = 30 independent biological samples) or peripheral blood (two-sided P = 0.35, Wilcoxon rank sum test, W = 83, 95% confidence interval 0.15 to 0.05, n = 30 independent biological samples) or proportion of T cell receptors shared between tumor and blood at baseline (twosided P = 0.62, Wilcoxon rank sum test, W = 117, 95% confidence interval -0.003 to 0.007, n = 29 independent biological samples), the time of surgery (two-sided P = 0.68, Wilcoxon rank sum test, W = 99, 95% confidence interval -0.004 to 0.008, n = 27 independent biological samples) or at cycle 2 of adjuvant treatment (P = 0.27, Wilcoxon rank sum test, W = 131, 95% confidence interval -0.002 to 0.009, n = 29 independent biological samples).
Mass cytometry.
Peripheral blood mononuclear cells were collected at baseline, at the time of surgery and after one or two cycles of adjuvant therapy, and prepared for mass cytometry analysis according to the Maxpar cell surface-staining protocol. Briefly, 0.5 × 10 6 to 3.5 × 10 6 cells were washed with phosphate buffered saline then resuspended in 5 µM Cell-ID cisplatin (Fluidigm) as a live/dead marker for 5 min at room temperature. After quenching with cell-staining buffer, the cells were incubated with a 24-marker panel ( Supplementary Table 6 ) for 30 min at room temperature. After washing with cell-staining buffer, cells were incubated overnight in 125 nM iridium intercalation solution (×1,000 dilution of 125 µM Cell-ID Intercalator-Ir in Maxpar Fix and Perm Buffer (Fluidigm)) to label intracellular DNA. Cells were then washed with cell-staining buffer and distilled water.
Events were subsequently acquired on a Helios mass cytometer (Fluidigm) in the University of California, Los Angeles Jonsson Comprehensive Cancer Center flow cytometry core and the data were analyzed as described previously 66 . After acquisition, data were normalized utilizing EQ four-element calibration beads (Fluidigm) and preprocessed to remove dead cells. Each dataset was then loaded into R with the flowCore package. The raw marker intensities were transformed utilizing hyperbolic inverse sine (arcsinh) with cofactor of 5. All samples were bead normalized, and each marker intensity was scaled to values between 0 and 1. All markers were included in the analysis. We concatenated a total of 84 samples and utilized unsupervised clustering to conduct cell population identification (Extended Data Fig. 6 ). Cell population identification was carried out using FlowSOM to assign cells into a 10-by-10 grid according to similarity, utilizing the self-organizing map algorithm. The resulting 100 vectors of marker expression (codes) were clustered using ConsensusClusterPlus hierarchical clustering with average linkage. After the codes were clustered into 2-20 clusters, the delta area was then calculated and used to define the appropriate number of clusters based on the elbow criterion. No specific cell population appeared to consistently predict survival in our analyses compared to studies in other cancer types [48] [49] [50] .
Multiplex fluorescent immunohistochemistry. Formalin-fixed paraffinembedded tissue was stained using fluorescent multiplex immunohistochemistry to spatially visualize and quantify the following markers: CD8, PD-1, CD45, GFAP and PD-L1, using the Opal 4-Color Manual IHC Kit and protocol (PerkinElmer). Slides were first de-paraffinized with xylene and rehydrated with an ethanol gradient. Heat-induced antigen retrieval was then performed on slides before each antibody application using pH9 antigen retrieval buffer (AR9, PerkinElmer) for CD8, CD45, PD-1 and PD-L1 antibodies; pH6 antigen retrieval buffer (AR6, PerkinElmer) was used for GFAP. The following antibody clones and dilutions paired with Opal tyramide signal amplification reagent were used and applied in the following order for each panel: CD8 (C8/144B, 1:5,000, Dako) with Opal 520, PD-L1 (SP142, 1:4,000, Spring Biosciences) and Opal 570, PD-1 (EPR4877, 1:50,000, Abcam) and Opal 650; CD45 (2B11+PD7/26, 1:1,000, Dako) and Opal 520, PD-L1 (SP142, 1:4,000). All slides were nuclear counterstained with Spectral DAPI (PerkinElmer), mounted (ProLong Diamond Antifade Mountant, Life Tech) and whole sections were imaged at ×20 resolution (0.32 µM pixel -1 ) using a Leica Aperio Versa 200 Slide Scanning Microscope equipped with a 16-bit Andor Zyla 5.5-megapixel fluorescence camera (Translational Pathology Core Laboratory). Eight-bit images were captured using the equipped filters: DAPI 350/460 excitation/emission (ex/em), green 495/537 ex/em, red 580/625 ex/em and Cy5 640/690 ex/em. Positive stain quantification and spatial cell analysis was performed using HALO image analysis software (Indica Labs). Positivity thresholds were determined using primary antibody-negative control slides for exclusion of auto-fluorescence and nonspecific background staining.
MRI acquisition and analysis. Anatomic magnetic resonance images were acquired for all patients in the current study using a 1.5T or 3T clinical MRI scanner, using pulse sequences supplied by the respective manufacturers and according to their local standard of care protocols. Standard anatomic images were obtained with the axial T1-weighted fast spin-echo sequence or magnetizationprepared rapid acquisition gradient-echo (MPRAGE) sequence (repetition time (ms)/echo time (ms)/inversion time (ms) = 400-3209/3.6-21.9/0-1238; slice thickness = 1.0-6.5 mm; intersection gap = 0-2.5 mm; number of averages = 1-2; matrix size = 176-512 × 256-512; and field of view = 24.0-25.6 cm). Additionally, T2-weighted fast spin-echo and fluid-attenuated inversion-recovery sequences were also obtained, and parameter-matched T1-weighted images enhanced with gadopentetate dimeglumine (Magnevist; Berlex; 0.1 mmol kg -1 ) were acquired shortly after contrast material injection. All trial scans were compliant with the consensus recommendations for the international standardized brain tumor imaging protocol 67 .
Linear registration was performed between all images (T2, fluid-attenuated inversion-recovery, pre-contrast T1, post-contrast T1) and post-contrast T1-weighted images at screening using a 12-degree-of-freedom linear transformation and a correlation coefficient cost function in FSL (FLIRT; FMRIB Software Library). Estimates of tumor volume were performed using contrastenhanced T1-weighted digital subtraction maps to exclude areas of post-surgical blood products or other sources of T1 shortening, as described previously [68] [69] [70] [71] . Initial segmentation was performed automatically using previously defined methodology [68] [69] [70] [71] and final segmented volumes were edited by an experienced investigator with more than 10 years of experience to exclude large vessels and any obvious non-tumor regions.
Statistics and reproducibility.
For mRNA quantification data, expression values were normalized using positive and negative controls and housekeeping genes and analyzed using the nSolver analysis software 4.0 (NanoString). Differential expression based on treatment group was assessed via a mixed negative binomial model for each gene with correction for multiple comparisons using the Benjamini-Hochberg adjustment. Gene set enrichment analysis was performed using the Kyoto Encyclopedia of Genes and Genomes gene collection in the Molecular Signatures Database 57,72 , with P values determined by hypergeometric test and corrected using a false discovery rate of 0.05 with n = 28 independent biological samples. The interferon-γ-associated gene expression profile score was calculated as previously described 34 .
To compute the differential abundance of T cell receptor clones, TCRβ rearrangements were detected by the immunoSEQ Assay for each patient's peripheral blood mononuclear cell samples at baseline (n = 29 independent biological samples), the time of surgery (n = 27 independent biological samples) and cycle 2 (n = 29 independent biological samples) and compared to the previous time point. Rearrangements with a count of under 10 between the two compared time points were excluded. For a TCRβ rearrangement to be considered significantly expanded or contracted, a two-sided binomial test with Benjamini-Hochberg adjustment was performed using a false discovery rate of 0.01. To determine whether there was a difference between the two groups, the number of expanded clones was compared using the Wilcoxon signed-rank test.
To evaluate differences between the neoadjuvant and adjuvant-only groups in mass cytometry data, we employed the generalized linear hypothesis function with the R function glht to test for the difference in marker expression, fitting fixed and mixed models using the stats and lme4 packages in R. To compare cell population proportions between groups, we employed a generalized linear mixed model using the sample identification and anonymized patient identifiers as random effects 73 . For differential analysis of marker expression by cell population, we calculated the median expression of 12 signaling markers in each cell population and sample, using these as the response variable in the linear mixed model. Progression-free survival (time from registration to disease progression per iRANO criteria or death) and overall survival (time from registration to death) were estimated using the PROC PHREG procedure in SAS. Multiple imputation with chained equations was utilized to account for missing biomarker data with five imputations of 50 iterations performed. Given the relatively low number of patients and large number of potential parameters with high correlation, we used an elastic net-regularized regression for variable selection. Both clinical (including IDH mutation status, age, sex, MGMT methylation status, number of previous relapses, Karnofsky performance status, steroid dose in milligrams at time of registration) and laboratory data (including mass cytometry cluster percentages, T cell receptor overlap, tumor T cell density, expanded tumor-associated T cell clones, interferon-γ-related signature scores, presence or absence of inducible PD-L1 expression on multiplex immunofluorescence) were considered potential covariates. We used fivefold cross-validation to obtain the value of λ that gave the minimum mean cross-validated error and determined the corresponding coefficients for each covariate. Variables with non-zero coefficients were then checked for collinearity and subsequently fitted into a Cox proportional hazards model, forcing in age and sex. Peripheral blood T cell receptor clonality and tumorinfiltrating lymphocyte fractions were standardized before fitting into the Cox regression owing to their wide ranges. As the tumor-infiltrating T cell fraction was a measurement taken at the time of surgery, we ran both a two-sample t-test (P = 0.52, t = 0.65, df = 27.6) and Wilcoxon rank sum test (P = 0.41, W = 133, n = 30 patients) to ensure that there was no significant imbalance between the two groups at alpha = 0.05 that could potentially introduce confounding into the model. We performed a Cox-Snell residual plot, which did not suggest any lack-of-fit for the multivariate Cox model. We then analyzed a representative cell cycle signatureassociated GSVA enrichment score (FARMER_BREAST_CANCER_CLUSTER_2) as a potential predictive biomarker. There was a clear imbalance between treatment groups (P = 0.02, t = -2.48, df = 27.8, two-sample t-test), indicating a correlation with the treatment variable; as such, it was not included on the initial multivariate Cox model to avoid confounding the treatment effect. We used a method previously described 41 , which extends the R 2 statistic to survival models with the R package PAmeasures, This R 2 value can then be utilized as an estimate that measures the ability of the prediction function to capture the variability of the response, even if the model is possibly mis-specified.
The primary objective of the trial was to evaluate whether administration of pembrolizumab (MK-3475) would induce statistically significant increases in tumor-infiltrating T lymphocyte density in recurrent/progressive GBM patients compared to an untreated concurrent control. The adjuvant-only group was considered an independent concurrent control to evaluate the tumor-infiltrating lymphocyte density in the neoadjuvant group, due to the infeasibility of multiple resections within a short time period for patients with recurrent glioblastoma. Based on our preliminary data, the mean tumor-infiltrating lymphocyte density was estimated to be 0.4 T cells per nucleated cell (s.d. = 0.5) in the control group. Fifteen patients per group was deemed sufficient to achieve 85% power to detect an increase of 0.5 in tumor-infiltrating lymphocyte density comparing the neoadjuvant group against the adjuvant-only group at an alpha of 0.05 (onesided) using a two-sample t-test. The three patients who withdrew consent before treatment and the two whose tumors were deemed non-evaluable on the basis of pathology protocol were replaced with randomized subjects to achieve a total of 15 patients per group to power our primary objective. To test for imbalance in patient characteristics between the two groups in age, sex, Karnofsky performance status, IDH mutation status and MGMT methylation status, we performed the Fisher exact test for categorical variables and Student t-test for continuous variables. Statistical analysis was performed with SAS version 9.2, GraphPad Prism version 6.01 or R version 3.4.3 or higher. All P values are two-tailed unless otherwise specified. The false discovery rate was controlled at 5% with the Benjamini-Hochberg procedure unless otherwise specified.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Code availability
R code is available in packages as described in the manuscript.
Data availability
RNA sequencing data are available in the Gene Expression Omnibus under accession number GSE121810, which includes source data for Fig. 2b and Extended Data Figs. 4 and 5. The remainder of data that support the findings of this study are available from the corresponding author on reasonable request.
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Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Sequence & imaging parameters
Parameter matched pre-and post-contrast (gadopentate dimegumine, 0.1 mmol/kg BW) T1-weighted images were acquired using either a 2D fast spin-echo or 3D gradient echo (MPRAGE, SPGR, or IR-SPGR) sequence (repetition time (msec)/echo time (msec)/ inversion time (msec) = 400-3209/3.6-21.9/0-1238; slice thickness = 1-6.5 mm; intersection gap = 0-2.5 mm; number of averages = 1-2; matrix size = 176-512 x 256-512; and field of view = 24-25.6 cm). 2D T2weighted fast spin-echo and fluid-attenuated inversion-recovery (FLAIR) images were also acquired but not used in the current study. All on trial scans were compliant with the consensus recommendations for the international standardized brain tumor imaging protocol ( Estimates of tumor volume were performed using contrast-enhanced T1-weighted digital subtraction maps to exclude areas of post-surgical blood products or other sources of T1 shortening. T1 subtraction maps were created by first performing linear registration as described above. Next, Gaussian normalization of image intensity was performed for both nonenhanced and contrast enhanced T1-weighted images using custom c-code courtesy of the National Institutes of Health Magnetoencaphalography Core Facility (3dNormalize; NIMH MEG Core, Bethesda, MD; kurage.nimh.nih.gov/ meglab/Med/3dNormalize), which normalizes image intensity by dividing each voxel by the standard deviation of the image intensity from the whole brain [SNor(x,y,z) = S (x,y,z)/stdWB], where S is raw image signal intensity, Nor is normalized, x,y,z are voxel coordinates, and stdWB is whole brain standard deviation. Next, voxel-by-voxel subtraction between normalized nonenhanced and contrast-enhanced T1-weighted images was performed using the Analysis of Functional NeuroImages software package (AFNI; 3dcalc; https://afni.nimh.nih.gov/). Image voxels with a positive (greater than zero) before-to-after change in normalized contrast enhancement signal intensity (ie, voxels increasing in MR signal after contrast agent administration) within T2-weighted FLAIR hyperintense regions were isolated to create the final T1 subtraction maps in order to exclude large vessels and other hyperintense regions outside the primary tumor area. Estimates of tumor volume included areas of contrast enhancement on T1 subtraction maps. Initial segmentation was performed automatically and final segmented volumes were edited by by an experienced independent observer with more than 10 years of experience to exclude large vessels and any obvious non-tumor regions.
Normalization
Intensity normalization was performed using custom c-code courtesy of the National Institutes of Health Magnetoencaphalography Core Facility (3dNormalize; NIMH MEG Core, Bethesda, MD; kurage.nimh.nih.gov/ meglab/ Med/3dNormalize), which normalizes image intensity by dividing each voxel by the standard deviation of the image intensity from the whole brain [SNor(x,y,z) = S (x,y,z)/stdWB], where S is raw image signal intensity, Nor is normalized, x,y,z are voxel coordinates, and stdWB is whole brain standard deviation.
Normalization template
Images were not normalized/registered to a standard template space. All images were registered to the patient-specific screening MRI exam as mentioned above.
Noise and artifact removal
No noise or artifact removal was performed. 
